TVGN

Tevogen Bio Holdings Inc. (TVGN) | Rumor.io

Tevogen Bio Holdings

TVGN

Attention (50-day avg)0%

Attention rank (50-day avg)#4,737

Bullish sentiment (50-day avg)0%

Price to earnings ratio2.86

Market capitalization44M

Earnings per share-6.29

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26.3M

Social

What share of all stock conversation is about TVGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

May 14

$TVGN's short interest is increasing, which could lead to a short squeeze, potentially moving the stock up 40-50%.
Tevogen Bio Holdings Inc. has a low float and high volatility, making it susceptible to significant price movements with relatively small capital inflows.
The company has a recent PIPE deal with $3M in capital and is expected to report corporate updates in an upcoming earnings report, which could drive further price appreciation.

Generated by AI

Sentiment

Of the messages about TVGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75.46% -12.62
Bearish	—	—	—	24.54% +12.62

Bullish· Dec 9

TVGN has impressive price action, reaching 60c in pre-market on high volume, indicating strong market interest.
The company's recent PR and revenue estimates suggest significant potential, with some analysts believing it could trade at $5.
TVGN has seen a substantial increase in trading volume, with some sessions experiencing 40x the average daily volume, indicating a high level of market activity.

Bearish· Aug 5

$TVGN's partnership with $MSFT may not be as beneficial as expected, as investors are dumping the stock and moving to other companies.
The stock's high volume and subsequent inability to move may indicate a lack of institutional support or a lack of momentum.
$TVGN's price has historically been highly volatile, with the stock experiencing significant declines even in the face of positive news.

Generated by AI

Topics

Of the messages about TVGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.6%
Announcements	—	—	—	64.17%
Controversies	—	—	—	1.07%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	33.16%

Announcements· Aug 5

Tevogen Bio Holdings Inc. ($TVGN) expands collaboration with Databricks and Microsoft to build the beta version of its PredicTcell model with a focus on oncology.
The PredicTcell model is being shifted from virology to oncology, with the goal of enhancing the model's capabilities and potentially leading to new revenue streams.
Tevogen Bio Holdings Inc. is expected to generate top-line revenue of nearly $1 billion in its launch year, with a cumulative 5-year estimate of $18 billion to $22 billion.

Technical Analysis· Oct 25

$TVGN is forming an ascending triangle on the 1-day chart and needs to break above $2.69 to continue its upward trend.
The stock has a strong bull flag forming on the daily chart, with a potential target of $3 if it breaks above $2.76.
Momentum is continuing in $TVGN, with the trend structure expected to remain stable, but traders are advised to keep an eye on larger highs and lows and take some risk off if the trend structure changes.

Generated by AI

Community

Of the messages about TVGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	57.09%
Newcomers	—	—	0%	42.91%

Mar 6

The reverse stock split of $TVGN has reduced the number of shares outstanding to 4.0M from 202.4M, potentially increasing the stock's value.
The acquisition of Apozeal Pharmaceutical by Tevogen Bio Holdings may boost the company's generics strategy and lead to increased stock performance.
A major volume surge is imminent for $TVGN, potentially signaling a breakout, and strategic options positioning could capitalize on the volatility.

Generated by AI

News

Tevogen Bio regains Nasdaq listing compliance status

Detailed price information for Tevogen Inc (TVGN-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Tevogen regains Nasdaq compliance with minimum market value requirement

19d agoInvesting.com

Tevogen Bio Holdings Rebrands as Tevogen Inc.

Detailed price information for Tevogen Inc (TVGN-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Tevogen Name Change Text: Tevogen Bio Holdings Inc. Becomes Tevogen Inc. WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Directors. The name change reflects Tevogen's ongoing evolution into a healthcare enterprise where science, technology, and patient care converge to shape the future of healthcare. The Company’s common stock and

2mo agoYahoo Finance

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

TEVOGEN Tevogen Initiatives WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is scheduled for Monday, August 24, 2026. The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof. Because the meeting date is more than 30 days after the

2mo agoYahoo Finance

Also Discussed

Investors talking about TVGN also mention

#	Name	Attention
1	Firefly Neuroscience IncAIFF	0%-0.01
2	Top Wealth Group Holding LimitedTWG	0%-0.01
3	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
4	SKK Holdings Ltd Class A Ordinary SharesSKK	0%new
5	Bright Minds Biosciences Inc.DRUG	0%new
6	Jiade Ltd. Class A Ordinary SharesJDZG	0%0
7	STEC - Santech Holdings Limited	——
8	Chanson International Holding Class A Ordinary SharesCHSN	0%0
9	Monopar Therapeutics Inc.MNPR	0%0
10	Neo-Concept International Group Holdings Limited Class A Ordinary SharesNCI	0.01%+0.01

Tevogen Bio Holdings Inc.

Healthcare
Biotechnology

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies using its ExacTcell™ platform to harness CD8+ cytotoxic T lymphocytes for treating infectious diseases, cancers, and neurological disorders. The company targets antigens present only on diseased cells to spare healthy tissue, enhancing safety through naturally occurring T cell receptors, with applications spanning oncology, neurology, and virology. Key product candidates include TVGN 489, which has completed Phase 1 trials for high-risk COVID-19 patients and is in Phase 1 for acute SARS-CoV-2 in B-cell suppressed individuals and Long COVID; TVGN 920 and TVGN 960 in preclinical stages for cervical and oropharyngeal cancers; TVGN 601 for multiple sclerosis; TVGN 930 for Epstein-Barr virus-associated lymphomas; and TVGN 116 for hepatitis B. Tevogen Bio Holdings Inc. also advances Tevogen.AI, applying proprietary predictive technologies like PredicTcell™ to accelerate drug development through immunologically active peptide identification. Founded in 2020 and headquartered in Warren, New Jersey, the company focuses on making therapies commercially viable and accessible to broad patient populations in the biotechnology sector.

Website

Location

15 Independence Boulevard

Warren, NJ, 07059

United States

Social

What share of all stock conversation is about TVGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.01

May 14

$TVGN's short interest is increasing, which could lead to a short squeeze, potentially moving the stock up 40-50%.
Tevogen Bio Holdings Inc. has a low float and high volatility, making it susceptible to significant price movements with relatively small capital inflows.
The company has a recent PIPE deal with $3M in capital and is expected to report corporate updates in an upcoming earnings report, which could drive further price appreciation.

Generated by AI

Sentiment

Of the messages about TVGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75.46% -12.62
Bearish	—	—	—	24.54% +12.62

Bullish· Dec 9

TVGN has impressive price action, reaching 60c in pre-market on high volume, indicating strong market interest.
The company's recent PR and revenue estimates suggest significant potential, with some analysts believing it could trade at $5.
TVGN has seen a substantial increase in trading volume, with some sessions experiencing 40x the average daily volume, indicating a high level of market activity.

Bearish· Aug 5

$TVGN's partnership with $MSFT may not be as beneficial as expected, as investors are dumping the stock and moving to other companies.
The stock's high volume and subsequent inability to move may indicate a lack of institutional support or a lack of momentum.
$TVGN's price has historically been highly volatile, with the stock experiencing significant declines even in the face of positive news.

Generated by AI

Topics

Of the messages about TVGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.6%
Announcements	—	—	—	64.17%
Controversies	—	—	—	1.07%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	33.16%

Announcements· Aug 5

Tevogen Bio Holdings Inc. ($TVGN) expands collaboration with Databricks and Microsoft to build the beta version of its PredicTcell model with a focus on oncology.
The PredicTcell model is being shifted from virology to oncology, with the goal of enhancing the model's capabilities and potentially leading to new revenue streams.
Tevogen Bio Holdings Inc. is expected to generate top-line revenue of nearly $1 billion in its launch year, with a cumulative 5-year estimate of $18 billion to $22 billion.

Technical Analysis· Oct 25

$TVGN is forming an ascending triangle on the 1-day chart and needs to break above $2.69 to continue its upward trend.
The stock has a strong bull flag forming on the daily chart, with a potential target of $3 if it breaks above $2.76.
Momentum is continuing in $TVGN, with the trend structure expected to remain stable, but traders are advised to keep an eye on larger highs and lows and take some risk off if the trend structure changes.

Generated by AI

Community

Of the messages about TVGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	57.09%
Newcomers	—	—	0%	42.91%

Mar 6

The reverse stock split of $TVGN has reduced the number of shares outstanding to 4.0M from 202.4M, potentially increasing the stock's value.
The acquisition of Apozeal Pharmaceutical by Tevogen Bio Holdings may boost the company's generics strategy and lead to increased stock performance.
A major volume surge is imminent for $TVGN, potentially signaling a breakout, and strategic options positioning could capitalize on the volatility.

Generated by AI

Tevogen Bio Holdings

Social

May 14

Bullish· Dec 9

Bearish· Aug 5

Announcements· Aug 5

Technical Analysis· Oct 25

Mar 6

Tevogen Bio regains Nasdaq listing compliance status

Tevogen regains Nasdaq compliance with minimum market value requirement

Tevogen Bio Holdings Rebrands as Tevogen Inc.

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Also Discussed

Tevogen Bio Holdings Inc.

Company Information

Location

Tevogen Bio regains Nasdaq listing compliance status

Tevogen regains Nasdaq compliance with minimum market value requirement

Tevogen Bio Holdings Rebrands as Tevogen Inc.

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Also Discussed

Social

May 14

Bullish· Dec 9

Bearish· Aug 5

Announcements· Aug 5

Technical Analysis· Oct 25

Mar 6